Low-dose captopril alone and in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension.
In this open, titrated dose clinical trial, captopril, when used in small doses (up to 150 mg daily) for 8 weeks (n = 5) and 4 months (n = 13) in patients suffering from mild to moderate essential hypertension, produced a fall in blood pressure both systolic and diastolic. The end point viz. supine diastolic blood pressure of 90 mmHg or less was reached in 6 out of 18 patients with captopril alone and in another 4 patients after the addition of hydrochlorothiazide (25 mg to 50 mg daily). In 4 more patients, a good response was observed but the end point was not reached. The response was fair in 1 and poor in 3 remaining patients. The side effects produced were only mild in nature and did not require any change in dosage schedule. No significant changes were produced in serum electrolytes, creatinine and blood counts.
D000328:Adult; D002216:Captopril / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D006852:Hydrochlorothiazide; D002216:Captopril